Secondary analysis of the phase III ARASENS trial (1273 patients with metastatic hormone-sensitive prostate cancer on darolutamide or placebo plus ADT and docetaxel): >97% received an efficacious docetaxel dose (RDI >80%); G-CSF was used in 42.4% vs 44.6%.
Secondary analysisn = 1,273
Ong et al. Use of concomitant G-CSF in maintaining efficacious dose and safe delivery of docetaxel in combination with darolutamide in ARASENS: A phase III study